CN116283828A - PARP1 inhibitor intermediate and preparation method and application thereof - Google Patents
PARP1 inhibitor intermediate and preparation method and application thereof Download PDFInfo
- Publication number
- CN116283828A CN116283828A CN202310054953.5A CN202310054953A CN116283828A CN 116283828 A CN116283828 A CN 116283828A CN 202310054953 A CN202310054953 A CN 202310054953A CN 116283828 A CN116283828 A CN 116283828A
- Authority
- CN
- China
- Prior art keywords
- mixing
- reacting
- steps
- structural formula
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 title claims abstract description 51
- 239000003112 inhibitor Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 title claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 7
- 125000005843 halogen group Chemical group 0.000 claims abstract description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 3
- 125000002560 nitrile group Chemical group 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 36
- 238000002156 mixing Methods 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 31
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000003999 initiator Substances 0.000 claims description 6
- WGKCIVUZMDDCDY-UHFFFAOYSA-N 2-bromoprop-1-ene;magnesium Chemical compound [Mg].CC(Br)=C WGKCIVUZMDDCDY-UHFFFAOYSA-N 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- 229910010082 LiAlH Inorganic materials 0.000 claims description 5
- FCDPQMAOJARMTG-UHFFFAOYSA-M benzylidene-[1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichlororuthenium;tricyclohexylphosphanium Chemical compound C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.CC1=CC(C)=CC(C)=C1N(CCN1C=2C(=CC(C)=CC=2C)C)C1=[Ru](Cl)(Cl)=CC1=CC=CC=C1 FCDPQMAOJARMTG-UHFFFAOYSA-M 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 239000011986 second-generation catalyst Substances 0.000 claims description 5
- WCOCYZXXISYZLN-UHFFFAOYSA-N B(F)(F)F.C=C.[K] Chemical compound B(F)(F)F.C=C.[K] WCOCYZXXISYZLN-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000012298 atmosphere Substances 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract description 43
- 239000012661 PARP inhibitor Substances 0.000 abstract description 6
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 238000013461 design Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 239000000543 intermediate Substances 0.000 description 32
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 229910052786 argon Inorganic materials 0.000 description 12
- 238000012544 monitoring process Methods 0.000 description 11
- -1 palladium metal complex Chemical class 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- 238000012512 characterization method Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000033590 base-excision repair Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- USFPINLPPFWTJW-UHFFFAOYSA-N tetraphenylphosphonium Chemical compound C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 USFPINLPPFWTJW-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses a PARP1 inhibitor intermediate, and a preparation method and application thereof. Relates to the technical field of drug molecular design and drug synthesis. A PARP1 inhibitor intermediate comprising the structure:
wherein R is 1 Selected from the group consisting of-Cl, -Br, -F, -I, -NO 2 and-NH 2 One of the following; wherein R is 2 Selected from benzyl, allyl, acetyl and (Boc) 2 At least one of O; wherein R is 3 One selected from-I, -Cl and-Br; wherein R is 4 Selected from C 1‑8 Alkyl, C 2‑8 Alkenyl, halogen substituted C 1‑8 At least one of an alkyl group, a nitrile group, a phenyl group, and a sulfonyl group. The PARP inhibitor can be used as a targeting drug to selectively kill BRCA mutant cells so as to play a role in killing tumors, and the PARP1 inhibitor intermediate of the invention is a key intermediate for synthesizing the PARP inhibitor and determines PARBased on the actual performance of the P inhibitor, the invention prepares a high-quality PARP1 inhibitor intermediate, which is favorable for PARP inhibitors with excellent activity of each layer.
Description
Technical Field
The invention relates to the technical fields of drug molecular design and drug synthesis, in particular to a PARP1 inhibitor intermediate and a preparation method and application thereof.
Background
Poly (ADP-ribose) polymerase (PARPs) is a ribozyme present in eukaryotic cells and is mainly involved in DNA repair, transcription, regulation and the like.
Among 18 members of the PARP family, PARP-1 has the highest intracellular content, and is most deeply studied, and ADP-ribose units are mainly catalyzed to transfer to nuclear receptor proteins by taking NAD+ as a substrate, so that a poly ADP-ribose polymer is formed, repair enzymes are guided to repair DNA gaps, and a key effect is played in a base excision repair path. In the current situation of extremely lack of high-quality targets in drug development at present, PARP-1 provides a few clinically verified anticancer targets for us.
Intermediates of different PARP1 inhibitors can synthesize active PARP1 inhibitors, and the prior PARP1 inhibitor intermediates still do not reach ideal performance. More importantly, the yield of the intermediate of the PARP1 inhibitor plays a decisive role in the yield of the PARP1 inhibitor, whereas the existing synthesis methods of the intermediate of the PARP1 inhibitor are not ideal.
Based on this, there is a need for a novel PARP1 inhibitor intermediate and a preparation method thereof, so as to promote the design, development and synthesis of more high-quality PARP1 inhibitors, promote the synthesis of PARP1 inhibitors with excellent activity, and promote the high-yield production of PARP1 inhibitors.
Disclosure of Invention
The first technical problem to be solved by the invention is as follows:
a PARP1 inhibitor intermediate is provided.
The second technical problem to be solved by the invention is as follows:
a process for preparing the PARP1 inhibitor intermediate is provided.
The third technical problem to be solved by the invention is:
use of said PARP1 inhibitor intermediate.
In order to solve the first technical problem, the invention adopts the following technical scheme:
a PARP1 inhibitor intermediate comprising the structure:
wherein R is 1 Selected from the group consisting of-Cl, -Br, -F, -I, -NO 2 and-NH 2 One of the following;
wherein R is 2 Selected from benzyl, allyl, acetyl and (Boc) 2 At least one of O;
wherein R is 3 One selected from-I, -Cl and-Br;
wherein R is 4 Selected from C 1-8 Alkyl, C 2-8 Alkenyl, halogen substituted C 1-8 At least one of an alkyl group, a nitrile group, a phenyl group, and a sulfonyl group.
According to the embodiments of the present invention, one of the technical solutions has at least one of the following advantages or beneficial effects:
the PARP inhibitor can be used as a targeting drug to selectively kill BRCA mutant cells so as to play a role in killing tumors, and the PARP1 inhibitor intermediate is a key intermediate for synthesizing the PARP inhibitor and determines the actual performance of the PARP inhibitor.
According to an embodiment of the invention, R 4 Selected from C 1-8 Alkyl, C 2-8 Alkenyl, halogen substituted C 1-8 At least one of the alkyl groups.
According to an embodiment of the invention, R 4 At least one selected from ethyl, propyl, butyl and isopropyl.
In order to solve the second technical problem, the invention adopts the following technical scheme:
a process for preparing the PARP1 inhibitor intermediate comprising the steps of:
s1, taking A0 as a starting material, and obtaining A1 through reaction;
S2A 1 is subjected to substitution reaction to obtain A2;
s3, mixing A2 with a first reducing agent, and reacting to obtain A3;
s4, mixing A3 with A3-1, and reacting to obtain A4;
s5, mixing A4 with Grubbs second generation catalyst, and carrying out catalytic reaction to obtain A5;
s6 mixing A5 with a composition containing R 2 Reacting the compounds of (2) to obtain A6;
s7, mixing A6 with a second reducing agent, and reacting to obtain A7;
s8, mixing A7 with iodine simple substance, and reacting to obtain the intermediate of the PARP1 inhibitor;
wherein, the structural formula of A0 is:
wherein, the structural formula of A1 is:
wherein, the structural formula of A2 is:
wherein, the structural formula of A3 is:
wherein, the structural formula of A3-1 is:
wherein, the structural formula of A4 is:
wherein, the structural formula of A5 is:
wherein, the structural formula of A6 is:
wherein, the structural formula of A7 is:
wherein R is 3 Selected from one of-Cl, -Br, -F and-I.
According to the embodiments of the present invention, one of the technical solutions has at least one of the following advantages or beneficial effects:
compared with the existing method, the preparation method of the PARP1 inhibitor intermediate has the advantages of easily obtained raw materials, high synthesis efficiency, extremely high yield and at least up to 95.98 percent.
According to an embodiment of the invention, the mass ratio of A0 to A1 is 80-100: :110-120..
According to an embodiment of the invention, the mass ratio of A0 to A1 is 99-100: :118-120..
According to an embodiment of the invention, the mass ratio of A1 to A2 is 100-120:70-80.
According to an embodiment of the invention, the mass ratio of A1 to A2 is 116-120:75-80.
According to an embodiment of the invention, the mass ratio of A2 to A3 is 60-79:50-60.
According to an embodiment of the invention, the mass ratio of A2 to A3 is 63-79:54-60.
According to an embodiment of the invention, the mass ratio of A3 to A4 is 20-30:8-10.
According to an embodiment of the invention, the mass ratio of A3 to A4 is 27-30:8-10.
According to an embodiment of the invention, the mass ratio of A4 to A5 is 5-10:5-12.
According to an embodiment of the invention, the mass ratio of A4 to A5 is 8-10:6-12.
According to an embodiment of the invention, the mass ratio of A5 to A6 is 2-10:3-12.
According to an embodiment of the invention, the mass ratio of A5 to A6 is 5-10:6-12.
According to an embodiment of the invention, the mass ratio of A6 to A7 is 2-10:3-6.
According to an embodiment of the invention, the mass ratio of A6 to A7 is 5-10:3-6.
According to an embodiment of the invention, the mass ratio of A7 to A8 (PARP 1 inhibitor intermediate) is 2-4:2-4.
According to an embodiment of the invention, the mass ratio of A7 to A8 (PARP 1 inhibitor intermediate) is 2-4:2-2.5.
According to an embodiment of the present invention, in step S1, the method further comprises the steps of: mixed concentrated HNO 3 Concentrated H 2 SO 4 And A0, obtaining A1 through reaction.
According to an embodiment of the present invention, in step S1, the method further comprises the steps of: collecting concentrated HNO 3 Cooling to 0-5 deg.c in a container, and dropping concentrated H 2 SO 4 After the dripping is finished, adding A0 in batches; after the reaction is completed, the reaction returns to normal temperature for 2 to 4 hours, the reaction solution is slowly dripped into ice water after the reaction is completed, and after the solid is separated out, the solution is filtered and leached to be neutral (pH is approximately equal to 6), the solid is dissolved by solvent, and saturated NaHCO is used 3 The organic phase is washed with solution, dried and concentrated to obtain A1.
According to one embodiment of the invention, in step S1, A0 is added in portions; after the addition, the reaction is carried out for 2 to 4 hours at normal temperature, specifically, the reaction time is selected from any one time or a section formed by any two times: 2h, 2.1h, 2.2h, 2.3h, 2.4h, 2.5h, 2.6h, 2.7h, 2.8h, 2.9h, 3.0h, 3.1h, 3.2h, 3.3h, 3.4h, 3.5h, 3.6h, 3.7h, 3.8h, 3.9h and 4.0h.
According to one embodiment of the invention, in step S1, the water is rinsed to a partial neutrality (ph≡6), where neutrality should be regarded as the presence of an adjustable pH interval, i.e. a pH value that the skilled person can choose from among this pH interval depending on the actual situation.
According to an embodiment of the present invention, the pH is at least selected from the pH range consisting of any one or both of the following pH values: 5.5, 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 6.8 and 7.0.
According to an embodiment of the present invention, in step S2, the method further comprises the steps of: mixing A1 with ethylene potassium trifluoroborate, and reacting to obtain A2.
According to an embodiment of the present invention, in step S2, the method further comprises the steps of: mixing A1, 4-dioxane, ethylene potassium trifluoroborate, TEA, water, dppf, pd (OAc) 2 Argon substitution and heating reaction overnight; extracting, drying, concentrating and purifying to obtain A2.
According to an embodiment of the present invention, in step S3, the method further comprises the steps of: mixing A2 with reduced iron powder and solvent, cooling to about 20 ℃, adding glacial acetic acid and concentrated hydrochloric acid, and reacting for 5-8h; cooling after reaction, regulating pH to 7-8, filtering, leaching, extracting, separating liquid, drying, concentrating and purifying to obtain A3.
According to one embodiment of the present invention, in step S3, glacial acetic acid and concentrated hydrochloric acid are added to react for 5 to 8 hours, specifically, the reaction time is selected from any one time or any two time intervals: 5.5h, 6.0h, 6.5h, 7.0h, 7.5h and 8.0h.
According to one embodiment of the present invention, step S4 further comprises a preparation method of A3-1, comprising the steps of: mixing 1, 4-diazabicyclo [2.2.2] octane-1, 4-diimmonium-1, 4-disulfonic acid and magnesium isopropenyl bromide, reacting, and adding a compound containing sulfonyl and halogen groups to obtain A3-1.
According to an embodiment of the present invention, in step S4, the method further comprises the steps of: mixing DABSO and THF, cooling to-50 to-40 ℃, adding magnesium isopropenyl bromide, controlling the temperature to-50 to-40 ℃, and reacting for 2-3h; cooling, dripping dilute hydrochloric acid for quenching, extracting, drying and concentrating; adding a solvent into the concentrated solution, carrying out water bath, dropwise adding a compound containing sulfonyl and halogen groups, reacting for 2 hours after the dropwise adding, extracting, drying and concentrating; adding solvent and A3 into the concentrated solution, water-bathing, dripping pyridine, and reacting overnight after dripping, wherein TLC monitoring reaction is advanced by one third; pouring the reaction liquid into a solvent, regulating the pH value to 4-5, extracting, drying, concentrating and purifying to obtain A4.
According to one embodiment of the present invention, in step S4, DABSO and THF are mixed and cooled to-50 to-40 ℃, specifically, the cooled temperature is selected from any one temperature or a temperature interval formed by any two temperatures: -50 ℃, -48 ℃, -46 ℃, -44 ℃, -42 ℃ and-40 ℃.
According to one embodiment of the present invention, in step S4, magnesium isopropenyl bromide is added, the temperature is controlled between-50 ℃ and-40 ℃, specifically, the temperature is selected from any one temperature or a temperature interval formed by any two temperatures: -50 ℃, -48 ℃, -46 ℃, -44 ℃, -42 ℃ and-40 ℃.
According to an embodiment of the present invention, in step S5, the method further comprises the steps of: under the protective atmosphere, mixing A4 with Grubbs second generation catalyst, heating to 40-50 ℃, and carrying out catalytic reaction to obtain A5.
According to one embodiment of the present invention, in step S5, mixing A4 with Grubbs second generation catalyst, heating to 40-50 ℃, specifically, the temperature after heating is selected from any one temperature or any two temperature ranges: 42 ℃, 44 ℃, 46 ℃, 48 ℃ and 50 ℃.
According to an embodiment of the present invention, in step S5, the method further comprises the steps of: mixing A4 with solvent, and heating to 40-60 deg.C under the protection of argon; slowly dripping a diluent of Grubbs 2nd catalyst, reacting for 2-4h after dripping, monitoring the residual 10% of the raw materials by LCMS, adding argon for replacement, reacting for 1.5-2h, monitoring the residual 2.1% of the raw materials by LCMS, and stopping the reaction; concentrating, pulping, and filtering to obtain A5.
According to one embodiment of the present invention, in step S5, A4 is mixed with a solvent, under the protection of argon, and the temperature is raised to 40-60 ℃, specifically, the temperature after the temperature is raised is selected from any one temperature or a temperature interval formed by any two temperatures: 42 ℃, 44 ℃, 46 ℃, 48 ℃, 50 ℃, 52 ℃, 54 ℃, 56 ℃, 58 ℃ and 60 ℃.
According to an embodiment of the present invention, in step S6, the method further comprises the steps of: mixing A5, carbonate-containing compound, containingR 2 And (3) reacting to obtain A6.
According to an embodiment of the present invention, in step S6, the method further comprises the steps of: mixing A5, carbonate-containing compound and solvent, and dropwise adding R under the protection of argon 2 After the dripping is finished, reacting for 4-6 hours, and completely reacting; extracting, drying, concentrating and purifying to obtain A6.
According to an embodiment of the present invention, in step S7, the method further comprises the steps of: mixing A6 and LiAlH at-10 to-15 DEG C 4 And (3) carrying out reaction to obtain A7.
According to one embodiment of the invention, in step S7, A6 is mixed with LiAlH at-10 to-15 DEG C 4 Specifically, the temperature may be selected and determined according to the actual situation. More specifically, the temperature is selected from a temperature interval consisting of any one or any two of the following temperatures: -10 ℃, -11 ℃, -12 ℃, -13 ℃, -14 ℃, -15 ℃.
According to an embodiment of the present invention, in step S7, the method further comprises the steps of: mixing A6 with solvent, argon protecting, cooling to-10 to-15 deg.C, and adding LiAlH in batches 4 Reacting for 2.5-5h after finishing adding; the reaction is complete; quenching, filtering, washing, concentrating and purifying to obtain 3A7.
According to one embodiment of the present invention, in step S7, A6 and a solvent are mixed, and the mixture is cooled to-10 to-15 ℃ under the protection of argon, and specifically, the temperature is selected and determined according to practical situations. More specifically, the temperature is selected from a temperature interval consisting of any one or any two of the following temperatures: -10 ℃, -11 ℃, -12 ℃, -13 ℃, -14 ℃ and-15 ℃.
According to one embodiment of the invention, in step S7, liAlH is added in portions 4 The reaction is carried out for 2.5 to 5 hours after the addition, specifically, the reaction time is selected from any one time or a section formed by any two times: 2.5h, 2.8h, 3.1h, 3.4h, 3.7h, 4.0h, 4.3h, 4.6h and 5.0h.
According to an embodiment of the present invention, in step S8, the method further comprises the steps of: mixing A7, an initiator, imidazole and iodine simple substance, and reacting to obtain the PARP1 inhibitor intermediate.
According to an embodiment of the present invention, in step S8, the method further comprises the steps of: mixing A7, initiator, imidazole and solvent, cooling to about 0deg.C, and dripping I 2 After dripping, reacting for 1-2h; the reaction is complete; adding sodium thiosulfate solid, extracting, drying, concentrating and purifying to obtain the PARP1 inhibitor intermediate.
According to one embodiment of the present invention, in step S8, I is added dropwise 2 After the dripping is finished, reacting for 1-2h, wherein the reaction time is selected from any one time or a section formed by any two times: 1.2h, 1.4h, 1.6h, 1.8h and 2.0h.
According to one embodiment of the invention, the addition of sodium thiosulfate solids can eliminate excess elemental iodine.
According to one embodiment of the present invention, a process for preparing the PARP1 inhibitor intermediate is routed as follows:
According to one embodiment of the present invention, in the process for preparing the PARP1 inhibitor intermediate, pyridine is added mainly as an acid binding agent.
According to an embodiment of the present invention, in the process for preparing the PARP1 inhibitor intermediate, pyridine may be replaced with other compounds having similar functions according to the actual situation, for example, pyridine may be replaced with at least one of triethylamine and diisopropylethylamine.
According to one embodiment of the present invention, in the process for preparing the PARP1 inhibitor intermediate, potassium carbonate is added mainly as an acid binding agent.
According to an embodiment of the present invention, in the method for preparing the PARP1 inhibitor intermediate, potassium carbonate may be replaced with an organic base or an inorganic base according to actual conditions. As one embodiment, the inorganic base may be sodium carbonate.
According to one embodiment of the present invention, a process for preparing the PARP1 inhibitor intermediate is routed as follows:
according to one embodiment of the invention, the process for preparing A3-3 is carried out as follows:
in another aspect, the invention also relates to the use of the PARP1 inhibitor intermediate for the preparation of PARP1 inhibitors. Including PARP1 inhibitor intermediates as described in the example of aspect 1 above. The application adopts all the technical schemes of the PARP1 inhibitor intermediate, so that the PARP1 inhibitor has at least all the beneficial effects brought by the technical schemes of the embodiment.
Additional features and advantages of the invention will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Detailed Description
The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to fall within the scope of the invention.
In an embodiment, the term "alkyl" refers to a saturated hydrocarbon containing primary (positive) carbon atoms, or secondary carbon atoms, or tertiary carbon atoms, or quaternary carbon atoms, or a combination thereof. Phrases containing this term, e.g., "C 1-8 Alkyl "refers to an alkyl group containing 1 to 8 carbon atoms. Suitable examples include, but are not limited to: methyl (Me, -CH) 3 ) Ethyl (Et, -CH) 2 CH 3 ) 1-propyl (n-Pr, n-propyl, -CH 2 CH 2 CH), 2-propyl (i-Pr, i-propyl, -CH (CH) 3 ) 2 ) 1-butyl (n-Bu, n-butyl, -CH) 2 CH 2 CH 2 CH 3 ) 2-methyl-1-propyl (i-Bu, i-butyl, -CH) 2 CH(CH 3 ) 2 ) 2-butyl (s-Bu, s-butyl, -CH (CH) 3 )CH 2 CH 3 ) 2-methyl-2-propyl (t-Bu, t-butyl, -C (CH) 3 ) 3), 1-pentyl (n-pentyl, -CH 2 CH 2 CH 2 CH 2 CH 3 ) 2-pentyl (-CH (CH) 3 )CH 2 CH 2 CH 3 ) 3-pentyl (-CH (CH) 2 CH 3 ) 2 ) 2-methyl-2-butyl (-C (CH) 3 ) 2 CH 2 CH 3 ) 3-methyl-2-butyl (-CH (CH) 3 )CH(CH 3 ) 2 ) 3-methyl-1-butyl (-CH) 2 CH 2 CH(CH 3 ) 2 ) 2-methyl-1-butyl (-CH) 2 CH(CH 3 )CH 2 CH 3 ) 1-hexyl (-CH) 2 CH 2 CH 2 CH 2 CH 2 CH 3 ) 2-hexyl (-CH (CH) 3 )CH 2 CH 2 CH 2 CH 3 ) 3-hexyl (-CH (CH) 2 CH 3 )(CH 2 CH 2 CH 3 ) 2-methyl-2-pentyl (-C (CH) 3 ) 2 CH 2 CH 2 CH 3 ) 3-methyl-2-pentyl (-CH (CH) 3 )CH(CH 3 )CH 2 CH 3 ) 4-methyl-2Amyl (-CH (CH) 3 )CH 2 CH(CH 3 ) 2 ) 3-methyl-3-pentyl (-C (CH) 3 )(CH 2 CH 3 ) 2 ) 2-methyl-3-pentyl (-CH (CH) 2 CH 3 )CH(CH 3 ) 2 ) 2, 3-dimethyl-2-butyl (-C (CH) 3 ) 2 CH(CH 3 ) 2 ) 3, 3-dimethyl-2-butyl (-CH (CH) 3 )C(CH 3 ) 3 and octyl (- (CH) 2 ) 7 CH 3 )。
In an embodiment, "alkenyl" refers to a hydrocarbon comprising a normal carbon atom, a secondary carbon atom, a tertiary carbon atom, or a cyclic carbon atom having at least one unsaturated site, i.e., a carbon-carbon sp2 double bond. Phrases containing this term, e.g., "C 2-8 Alkenyl "refers to alkenyl groups containing 2 to 8 carbon atoms. Suitable examples include, but are not limited to: vinyl (-ch=ch) 2 ) Propenyl (-CH) 2 CH＝CH 2 ) Cyclopentenyl (-C) 5 H 7 ) And 5-hexenyl (-CH) 2 CH 2 CH 2 CH 2 CH＝CH 2 )。
In embodiments, halogen "or" halo "refers to F, cl, br or I.
In embodiments, "halo substituted" means that an optional amount of H at any optional position on the corresponding group is substituted with halo, e.g., fluoromethyl, including monofluoromethyl, difluoromethyl, trifluoromethyl.
The reagents, methods and apparatus employed in the present invention, unless otherwise specified, are all conventional in the art.
Examples
A PARP1 inhibitor intermediate comprising the structure:
the preparation of the PARP1 inhibitor intermediate comprises the following steps:
specifically, the preparation of the PARP1 inhibitor intermediate comprises the following steps:
step 1
Taking concentrated HNO at room temperature 3 (65%, 133.5g,13.7mol,3.2 eq) in a 1L three-necked flask, cooling the ice-water bath to 5 ℃ C., slowly adding concentrated H dropwise 2 SO 4 (98.3%, 213g,2.14mol,5.0 eq) after the addition, A0 (99.58 g,0.42mol,1.0 eq) was added in 5 portions; after the addition, the reaction is carried out for 2 hours at normal temperature, and TLC monitoring shows that the reaction is finished; slowly dripping the reaction solution into 1.5L ice water, precipitating a large amount of solid, filtering, leaching with water to neutrality (pH is about 6), dissolving the solid with 300ml EA, and dissolving the solid with saturated NaHCO 3 The EA phase was washed with solution, and the organic phase was dried and concentrated to give 118.5g of pale yellow solid A1 in 99.75% yield.
Wherein, the characterization data of A1 is as follows:
1 H-NMR(500MHz,CDCl 3 )δ8.854-8.53(d,J＝6.6Hz,1H),7.59-7.58(d,J＝9.3Hz,1H),3.98(s,3H)。
step 2
A1 (116.64 g, 0.319 mol,1 eq) was added to a 5L three-necked flask at room temperature followed by 1, 4-dioxane (2.1L), ethylene potassium trifluoroborate (62.72 g, 0.268 mol,1.1 eq), TEA (63.5 g, 0.6278 mol,1.5 eq), water (1.4L), dppf (35.41 g,0.0638mol,0.15 eq), pd (OAc) 2 (14.7 g,0.0645mol,0.15 eq), argon substitution, and heating to 80 ℃ for reaction overnight; the TCL monitors the completion of the reaction; 1L of water and 1L of EA are added for extraction and separation, the aqueous phase is extracted for 3 times by EA, the organic phases are combined, dried, concentrated and stirred by silica gel, and the mixture is purified by column chromatography to obtain 75.18g of yellow solid A2 with the yield of 79.6 percent.
Wherein, the characterization data of A2 is as follows:
1 H NMR(500MHz,CDCl 3 )δ8.62-8.61(d,J＝6.5Hz,1H),7.39-7.37(d,J＝10.9Hz,1H),7.26–7.20(dd,1H),5.87-5.84(d,J＝17.2Hz,1H),5.66-5.64(d,J＝11.0Hz,1H),3.98(s,3H)。
step 3
A2 (63.3 g,0.281mol,1.0 eq), reduced iron powder (78.5 g,1.405mol,5.0 eq) and methanol (1.35L, 25V) are added into a 5L three-necked flask in sequence at room temperature, the temperature is reduced to about 20 ℃, glacial acetic acid (158.25 ml, 2.5V) is added, concentrated hydrochloric acid (30%, 32ml, 0.5V) is slowly added dropwise, and RT reaction is carried out for 5h; TLC monitoring reaction is complete; cooling in ice water bath, slowly adding NaHCO 3 The solid is adjusted to pH 7-8, filtered, the filter cake is leached by EA, saturated saline water is added into the filtrate to extract and separate liquid, and the organic phase is dried, concentrated, mixed with silica gel and purified by column chromatography to obtain 54.85g yellow solid A3 with the yield of 90.3 percent.
Wherein, the characterization data of A3 is as follows:
m/z 196(M+H)；
1 H NMR(500MHz,CDCl 3 )δ7.23-7.22(d,J＝6.2Hz,1H),7.07-7.05(d,J＝11.5Hz,1H),6.74-6.68(dd,J＝17.4,11.1Hz,1H),5.74-5.71(d,J＝17.4Hz,1H),5.47-5.45(d,J＝11.1Hz,1H),3.90(s,3H)。
step 4
DABSO (33.6 g,0.14mol,1.0 eq) was added to a 2L three-necked flask at room temperature, THF (340 ml, 10V) was added, the temperature was reduced to-40℃and magnesium isopropenyl bromide (0.5M, 700ml,0.35mol,2.5 eq) was added dropwise, the temperature was controlled between-50 and-40℃and the reaction was resumed for 2h after the completion of the dropwise addition; cooling, dripping dilute hydrochloric acid (300 ml) for quenching, extracting with MTBE for 3 times, drying, concentrating; DCM (340 ml, 10V) was added to the concentrate, water-bath, sulfonyl chloride (45.3 g,0.335mol,2.4 eq) was added dropwise, reacted for 2h after the addition, then the reaction was added dropwise to ice water (300 ml), extracted 3 times with MTBE, dried, concentrated; DCM (340 ml, 10V) and A3 (27.3 g,0.14mol,1.0 eq) were added to the concentrate, water-bath, pyridine (33.2 g,0.42mol,3.0 eq) was added dropwise, after the addition, the reaction was allowed to proceed overnight, and TLC monitoring the reaction was one third advanced; the reaction solution was poured into 300ml of water, the pH was adjusted to 4 to 5 with dilute hydrochloric acid, extracted 3 times with DCM, dried, concentrated, stirred with silica gel and purified by column chromatography to give 8.2g of orange solid A4 with a yield of 19.6%.
Wherein, the characterization data of A4 is as follows:
m/z 300(M+H)；
1 H NMR(500MHz,CDCl 3 )δ7.89-7.88(d,J＝6.5Hz,1H),7.27–7.25(d,1H),6.98 -6.92(dd,J＝17.3,11.1Hz,1H),6.44(s,1H),6.02(s,1H),5.84-5.80(d,J＝17.4Hz,1H),5.68(s,1H),5.61-5.58(d,J＝11.0Hz,1H),3.92(s,3H),2.13(s,3H)。
step 5
A4 (8.2 g,0.0274mol,1.0 eq) was added to a 2L single-necked flask at room temperature, DCM (1.2L, 150 v) was added, under argon protection, and the temperature was raised to 40 ℃; weighing Grubbs 2nd catalyst (1.64 g, 20%wt) and dissolving in 70ml DCM, slowly dripping a diluent of the Grubbs 2nd catalyst, reacting for 2 hours after dripping, monitoring the residual 10% of the raw material by LCMS, supplementing argon and replacing, reacting for 1.5 hours again, monitoring the residual 2.1% of the raw material by LCMS, and stopping the reaction; concentrated, slurried with DCM (10 ml) and n-heptane (50 ml) and filtered to give 6g of white solid A5 in 80.64%.
Wherein, the characterization data of A5 is as follows:
m/z 294(M+Na)；
1 H NMR(500MHz,CDCl 3 )δ7.64-7.62(d,J＝5.9Hz,1H),7.14-7.12(d,J＝10.2Hz,1H),6.88(s,1H),3.96(s,3H),2.40(s,3H)。
step 6
A5 (5.8 g,0.0213mol,1.0 eq), potassium carbonate (5.91 g,0.0427mol,2.0 eq) and DMF (30 ml, 5V) were added to a 100ml single-necked flask at room temperature, under the protection of argon, p-methoxybenzyl chloride (3.68 g,0.0234mol,1.1 eq) was added dropwise, after the addition, the reaction was completed by TLC monitoring; the reaction solution was poured into 150ml of water, 100ml of EA was added to extract, the aqueous phase was extracted 2 times with EA, and the organic phases were combined, dried, concentrated, stirred with silica gel and purified by column chromatography to give 6g of white solid A6 in a yield of 71.145.
Wherein, the characterization data of A6 is as follows:
m/z 414(M+Na)；
1 H NMR(500MHz,DMSO)δ7.84-7.83(d,J＝6.0Hz,1H),7.55-7.53(d,J＝10.9Hz,1H),7.29(s,1H),7.18-7.16(d,J＝8.5Hz,2H),6.88-6.86(d,J＝8.5Hz,2H),5.14(s,2H),3.86(s,3H),3.71(s,3H),2.34(s,3H)。
step 7
A6 (5.6 g,0.0143mol,1.0 eq) and THF (60 ml, 10V) were added at room temperature into a 100ml three-necked flask, cooled to-10℃under argon, and added in portions with LiAlH 4 (2.18 g,0.0572mol,4.0 eq) and 2.5h after addition; TLC monitoring reaction is complete; slowly dropwise adding 10ml of methanol for quenching, filtering with kieselguhr, washing a filter cake with EA, concentrating, stirring with silica gel, and purifying by column chromatography to obtain 3.3g of yellow solid A7 with the yield of 63.47%.
Wherein, the characterization data of A7 is as follows:
m/z 386(M+Na)；
1 H NMR(500MHz,CDCl 3 )δ7.30-7.29(d,J＝6.1Hz,1H),7.20-7.18(d,J＝8.5Hz,2H),6.98-6.95(d,J＝9.7Hz,1H),6.81-6.79(d,J＝8.6Hz,2H),6.77(s,1H),5.05(s,2H),4.71(s,2H),3.76(s,3H),2.36(s,3H)。
step 8
A7 (2.0 g,0.0055mol,1.0 eq) and PPh were added at room temperature 3 (2.23 g,0.0083mol,1.5 eq), imidazole (0.75 g,0.01 mol,2.0 eq) and DCM (50 ml, 25V) were added to a 250ml three-necked flask, cooled to 0℃and weighed I 2 (2.1 g,0.0083mol,1.5 eq) was dissolved in 50ml DCM and I was slowly added dropwise 2 After dripping, reacting for 1h; TLC monitoring reaction is complete; the reaction solution was poured into 150ml of water, a small amount of sodium thiosulfate solid was added, and stirred until the organic phase became pale yellow in color, extracted 3 times with DCM, dried, concentrated, stirred with silica gel, and purified by column chromatography to give 2.5g of yellow solid A8 in a yield of 95.98%.
Wherein, the characterization data of A8 is as follows:
m/z 496(M+Na)；
1 H NMR(500MHz,CDCl 3 )δ7.19-7.17(d,J＝8.5Hz,2H),7.13-7.11(d,J＝6.4Hz,1H),6.95-6.93(d,J＝9.4Hz,1H),6.83-6.81(d,J＝8.6Hz,2H),6.74(s,1H),5.02(s,2H),4.34(s,2H),3.76(d,J＝7.5Hz,3H),2.35(s,3H)。
the foregoing is merely exemplary embodiments of the present invention and are not intended to limit the scope of the present invention, and all equivalent modifications made by the present invention or direct or indirect application in the relevant art are intended to be included in the scope of the present invention.
Claims (10)
1. A PARP1 inhibitor intermediate, characterized in that: the structure comprises the following steps:
wherein R is 1 Selected from the group consisting of-Cl, -Br, -F, -I, -NO 2 and-NH 2 One of the following;
wherein R is 2 Selected from benzyl, allyl, acetyl and (Boc) 2 At least one of O;
wherein R is 3 One selected from-I, -Cl and-Br;
wherein R is 4 Selected from C 1-8 Alkyl group,C 2-8 Alkenyl, halogen substituted C 1-8 At least one of an alkyl group, a nitrile group, a phenyl group, and a sulfonyl group.
2. A process for preparing a PARP1 inhibitor intermediate according to claim 1, characterized in that: the method comprises the following steps:
s1, taking A0 as a starting material, and obtaining A1 through reaction;
S2A 1 is subjected to substitution reaction to obtain A2;
s3, mixing A2 with a first reducing agent, and reacting to obtain A3;
s4, mixing A3 with A3-1, and reacting to obtain A4;
s5, mixing A4 with Grubbs second generation catalyst, and carrying out catalytic reaction to obtain A5;
s6 mixing A5 with a composition containing R 2 Reacting the compounds of (2) to obtain A6;
s7, mixing A6 with a second reducing agent, and reacting to obtain A7;
s8, mixing A7 with iodine simple substance, and reacting to obtain the intermediate of the PARP1 inhibitor;
wherein, the structural formula of A0 is:
wherein, the structural formula of A1 is:
wherein, the structural formula of A2 is:
wherein, the structural formula of A3 is:
wherein, the structural formula of A3-1 is:
wherein, the structural formula of A4 is:
wherein, the structural formula of A5 is:
wherein, the structural formula of A6 is:
wherein, the structural formula of A7 is:
wherein R is 3 Selected from one of-Cl, -Br, -F and-I.
3. The method according to claim 2, characterized in that: in step S1, the method further includes the following steps: mixed concentrated HNO 3 Concentrated H 2 SO 4 And A0, obtaining A1 through reaction.
4. The method according to claim 2, characterized in that: in step S2, the method further includes the following steps: mixing A1 with ethylene potassium trifluoroborate, and reacting to obtain A2.
5. The method according to claim 2, characterized in that: in the step S4, the preparation method of A3-1 is also included, and comprises the following steps: mixing 1, 4-diazabicyclo [2.2.2] octane-1, 4-diimmonium-1, 4-disulfonic acid and magnesium isopropenyl bromide, reacting, and adding a compound containing sulfonyl and halogen groups to obtain A3-1.
6. The method according to claim 2, characterized in that: in step S5, the method further includes the following steps: under the protective atmosphere, mixing A4 with Grubbs second generation catalyst, heating to 40-50 ℃, and carrying out catalytic reaction to obtain A5.
7. The method according to claim 2, characterized in that: in step S6, the method further includes the steps of: mixing A5, carbonate-containing compound, R-containing 2 And (3) reacting to obtain A6.
8. The method according to claim 2, characterized in that: in step S7, the method further includes the steps of: mixing A6 and LiAlH at-10 to-15 DEG C 4 And (3) carrying out reaction to obtain A7.
9. The method according to claim 2, characterized in that: in step S8, the method further includes the steps of: mixing A7, an initiator, imidazole and iodine simple substance, and reacting to obtain the PARP1 inhibitor intermediate.
10. Use of a PARP1 inhibitor intermediate according to claim 1 for the preparation of a PARP1 inhibitor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310054953.5A CN116283828A (en) | 2023-02-03 | 2023-02-03 | PARP1 inhibitor intermediate and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310054953.5A CN116283828A (en) | 2023-02-03 | 2023-02-03 | PARP1 inhibitor intermediate and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116283828A true CN116283828A (en) | 2023-06-23 |
Family
ID=86815826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310054953.5A Pending CN116283828A (en) | 2023-02-03 | 2023-02-03 | PARP1 inhibitor intermediate and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116283828A (en) |
-
2023
- 2023-02-03 CN CN202310054953.5A patent/CN116283828A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI781996B (en) | Methods of synthesizing an mcl-1 inhibitor | |
| CN108101820B (en) | Synthesis process and intermediate of chiral pyrrolidine | |
| EP1740593B1 (en) | Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i | |
| TWI720803B (en) | Process for the preparation of a pde4 inhibitor | |
| JP2013523700A (en) | Method for producing aminobenzofuran derivative | |
| EP3450426A1 (en) | Method for synthesizing silodosin and intermediate thereof | |
| CN103965280A (en) | Preparation method of fulvestrant intermediate | |
| CN110862354B (en) | Bifunctional 1,2, 3-triazole derivative intermediate, preparation method and application | |
| CN108864160A (en) | The preparation method of boron-containing small molecules | |
| CN116283828A (en) | PARP1 inhibitor intermediate and preparation method and application thereof | |
| CN112321467A (en) | Preparation method of (2S,3R) -p-methylsulfonylphenylserine ethyl ester | |
| CN108840868B (en) | The preparation method and application of trypoline ketone compounds with anti-tumor activity | |
| CN105753733A (en) | AHU377 crystal form and preparation method and uses thereof | |
| CN106986837A (en) | A kind of preparation method of azole compounds | |
| CN105228987A (en) | For the preparation of the method for pyridazine compound | |
| JP2002520325A (en) | Method for producing 4- (3-pyridinyl) -1H-imidazole and intermediate used | |
| CN107602473B (en) | Preparation method of estrogen receptor ligand | |
| CN114644612A (en) | Preparation method of benzodiazepine neuroleptic intermediate compound | |
| CN108017522B (en) | Preparation process of 2, 6-dibromobenzene methane sulfonyl chloride | |
| CN103201278A (en) | Method for preparing zidovudine and intermediate thereof | |
| CN110028443B (en) | Preparation method of tricyclic compound drug intermediate for regulating FXR activity | |
| CN110423204B (en) | Preparation method of pranlukast intermediate | |
| CN116283512A (en) | Method for synthesizing vilanabro and salts thereof | |
| CN108997236A (en) | A kind of preparation method of Anastrozole impurity | |
| CN114685553B (en) | Preparation method of idecalcitol intermediate and intermediate thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |